Premium Company Profile Novavax

Novavax is a biopharmaceutical company focused on developing vaccines against the H5N1, H9N2 and other subtypes of avian influenza with pandemic potential as well as vaccines that protect against seasonal influenza. These vaccines leverage the company's virus-like particle (VLP) platform technology, Novasome adjuvants and unique production technology.

Report Highlights
Novavax is focused on creating vaccines for a range of infectious diseases. The company's Estrasorb is the first topical emulsion for estrogen therapy approved by the FDA for the treatment of moderate to severe vasomotor symptoms associated with menopause. The company also markets Gynodiol used for estrogen replacement therapy. The company's total revenues declined at a CAGR of 25% during 2002-2006, from $15 million to $5 million. The major reason for revenue decline was the decreasing product sales. Product sales of the company decreased at a CAGR of 34% during 2002-2006, from $13 million to $3 million. The company's total revenues would increase at a CAGR of 12% during 2006-2010 from $5 million to $8 million. The company's biggest contributor to revenue growth out to 2010 will be revenues from contract research and development.
[Fade out the market survey infos]

Overview 1
Catalyst 1
Summary 1
Company Structure 7
Company Overview and Key Facts 7
Business Description 8
History 10
Company Financials 12
Stock Market Performance 12
P&L 13
Balance Sheet 16
Cash Flow 16
Business Segment Performance 17
Products & Services 19
Marketed Products 19
Pipeline Products 20
AC Forecast Product Sales 21
Competitors and Strategic Business Relationships 23
Key Competitors 23
Key Suppliers 23
Key Clients 24
Shareholding Structure 25
Strategy 26
Company View 26
Corporate Strategy 26
SWOT Analysis 28
Overview 28
Strengths 29
Weaknesses 30
Opportunities 31
Threats 32
Value Chain Analysis 33
Overview 33
Discovery and Product Development 33
Manufacturing 34
Scorecard 35
Overview 35
Scorecard Analysis 36
Key Employees 37
List of Key Employees 37
Key Employee Biographies 38
Financial and Operational Overview 42
Financial and Operational Overview 42
Key Industry Specific Ratios 44
APPENDIX 45
Ask the analyst 45
Datamonitor consulting 45
Disclaimer 45
[Fade out table of contents]

Table 1: Novavax - Key Facts 7
Table 2: Novavax - Year-End Share Price and Market Capitalization, 2002-2006 ($) 12
Table 3: Novavax - Key Events Impacting Share Price Performance 12
Table 4: Novavax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Table 5: Novavax - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 15
Table 6: Novavax - Balance Sheet, 2002-2006 ($ Mn) 16
Table 7: Novavax - Cash Flow, 2002-2006 ($ Mn) 16
Table 8: Novavax - Revenue Breakdown by Division, 2002-2006 ($ Mn) 17
Table 9: Novavax - Marketed Products 19
Table 10: Novavax - Collaboration Products 20
Table 11: Novavax - Forecast Sales, 2006-2010 ($ Mn) 21
Table 12: Novavax - Key Competitors 23
Table 13: Novavax - Key Clients 24
Table 14: Novavax – Key Shareholders 25
Table 15: Novavax - SWOT Analysis Summary 28
Table 16: Novavax – Value Chain Analysis 33
Table 17: Novavax - Scorecard 35
Table 18: Novavax - Key Employees 37
Table 19: Novavax - Financial and Operational Overview 42
Table 20: Novavax - Key Industry Specific Ratios 44


Figure 1: Novavax - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 14
Figure 2: Novavax - Key Strategic Revenues, 2002-2006 ($ Mn) 18
Figure 2: Novavax - Key Strategic Revenues, 2006-2010 ($ Mn) 22
[Fade out list of tables / figures]